Company / R&D Expense
Sarepta Therapeutics R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.5B
FY2025
5-year range
$722.3M / $1.5B
FY2021-FY2025
Trend
+89.2%
vs FY2024
Sector context
#14 of 210
Health Care
What the data says
Among 210 Health Care companies, Sarepta Therapeutics is in the top 7% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $46M in FY2018 to $1.5B in FY2025.
Based on SEC 10-K filings.
$1.5B in FY2025 with a 5-year CAGR of +30.5%. Top quartile in the Health Care sector.
Improved from $877M to $1.5B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +28.2%
- 5-Year CAGR
- +30.5%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 210This company $1.5B Sector average $644.1M
▼
+136.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +30.5%, indicating consistent growth.
- In FY2025, r&d expense increased 89.2% year-over-year.
- Ranks #14 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.5B | +89.2% |
| FY2024 | $804.5M | -8.3% |
| FY2023 | $877.4M | +21.5% |
| FY2022 | $722.3M | -6.3% |
| FY2021 | $771.2M | +91.9% |
| FY2020 | $401.8M | +343.8% |
| FY2019 | $90.6M | +96.0% |
| FY2018 | $46.2M | -72.3% |
| FY2017 | $166.7M | -11.5% |
| FY2016 | $188.3M | +28.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026